A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Co najmniej jeden guz dający się zmierzyć na badaniach obrazowych
- •Poprzednie leczenie musi być ukończone i skutki uboczne wyleczone lub zminimalizowane do poziomu Grade 1
- •Rakomięśni lub cytologicznie potwierdzony rak żołądka, połączenia żołądka i przełyku, lub przełyku (Kohorta A)
- •Nie reagujący na pierwsze leczenie lub progresja po pierwszym leczeniu systemowym zawierającym chemię
- •Rakomięśni lub cytologicznie potwierdzony rak płaskonabłonkowy przełyku (Kohorty B i C)
- •Chęć udostępnienia próbek guza do badań laboratoryjnych
- •Informacja o wyniku testu PD-L1 z poprzedniego badania (Kohorta B)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
The University of Arizona Cancer Center
Tucson, United States
City of Hope
Duarte, United States
University of Colorado - Aurora Cancer Center
Aurora, United States
Winship Cancer Center - Emory University
Atlanta, United States
Ochsner Health
New Orleans, United States
Henry Ford Health System
Detroit, United States
Comprehensive Cancer Center of Nevada
Las Vegas, United States
Christus St Vincent Regional Medical Center
Santa Fe, United States
START New York
Lake Success, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Icahn School of Medicine at Mount Sinai
New York, United States
University of Pittsburg Medical Center _UPMC Hillman Cancer Center
Pittsburgh, United States
Prisma Health Cancer Institute
Greenville, United States
SCRI Oncology Partners
Nashville, United States
Texas Oncology - Central South
Austin, United States
START San Antonio, LLC.
San Antonio, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
START Mountain Region, LLC.
West Valley City, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Oncology Associates
Norfolk, United States
Changhua Christian Hospital
Chang-hua, Taiwan
E-Da Cancer Hospital
Kaohsiung City, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
China Medical University Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Mackay Memorial Hospital
Taipei, Taiwan
Trial contact
Clinical Operations Team
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.